secwatch.observer — SEC 8-K summary
======================================

Issuer:     TANDEM DIABETES CARE INC (TNDM)
CIK:        0001438133
Form:       8-K
Filed at:   2022-02-22T23:59:59+00:00
Accession:  0001438133-22-000020
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 2.0, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tandem Diabetes Q4 sales $210M (+25% YoY); FY2021 sales $703M (+41%); 2022 guide $845-860M
--------------------------------------------------------------------------------

- Full-year 2021 sales $702.8M (+41% YoY); net income $15.6M vs loss $34.4M in 2020.
- Q4 2021 sales $210.0M (+25% YoY); gross margin 54%; operating income $12.7M.
- 2022 guidance: sales $845-860M (20-22% growth); adjusted EBITDA margin 14-15% of sales.
- Worldwide pump shipments 128,312 in 2021, up 41% YoY.
- Appointed David Berger as EVP, COO effective Feb 3, 2022; board chair retainer cut from $115K to $50K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438133/000143813322000020/0001438133-22-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438133/000143813322000020/tndm-20220203.htm
  HTML page:      https://secwatch.observer/filing/0001438133-22-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer